{
    "symbol": "DCPH",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 07:21:08",
    "content": " We anticipate a number of important milestones, including the presentation of initial data from the ongoing Phase 1 monotherapy dose escalation study of DCC-3116 at ESMO next month; and initiation of three combination cohorts with MEK and KRAS G12C inhibitors; continued enrollment of the Phase 3 MOTION study of vimseltinib in TGCT; and the presentation of updated data from the ongoing Phase 1/2 study also at ESMO next month; and finally, nomination of a development candidate from our pan-RAF program later this year. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}